Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | ENPP1 | P22413 | 5/20 | 0.46 |
| ▸ | ENPP3 | O14638 | 5/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886403 | 0.81 | CA2 (0.46) | CA12CA2MEN1KMT2ACA9 | |
| SCHEMBL2881517 | 0.81 | MEN1 (0.49) | CA12CA2ENPP1ENPP3ENPP2 | |
| SCHEMBL5734712 | 0.81 | TDP1 (0.62) | CA12CA2ENPP1ENPP3ENPP2 | |
| SCHEMBL6862618 | 0.81 | SOS1 (0.63) | CA12CA2ENPP1ENPP3ENPP2 | |
| SCHEMBL3792465 | 0.81 | TDP1 (0.56) | CA12CA2ENPP1ENPP3ENPP2 | |
| SCHEMBL687580 | 0.81 | TDP1 (0.61) | CA12CA2ENPP1ENPP3ENPP2 | |
| SCHEMBL926461 | 0.80 | CA12 (0.51) | CA12CA2ENPP1ENPP3ENPP2 | |
| SCHEMBL2067020 | 0.79 | CA12 (0.51) | CA12CA2ENPP1ENPP3ENPP2 | |
| SCHEMBL22558454 | 0.78 | AKR1C3 (0.55) | CA12CA2ENPP1ENPP3ENPP2 | |
| SCHEMBL6304328 | 0.78 | ENPP1 (0.52) | CA12CA2ENPP1ENPP3ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776893-B2 | Use of PDE4 inhibitors for the treatment of diabetes mellitus | NYCOMED GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20060281745-A1 | Use of pde4 inhibitors for the treatment of diabetes mellitus | ALTANA PHARMA AG (DE) | 2006-12-14 | — | — | US | disclosed |
| EP-1650193-A2 | 6-Phenylphenanthridines with PDE-IV inhibiting activity | ALTANA Pharma AG (DE) | 2006-04-26 | — | — | EP | disclosed |
| EP-1147089-B1 | PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | ALTANA PHARMA AG (DE) | 2005-12-07 | — | — | EP | disclosed |
| WO-2005023253-A1 | USE OF PDE4 INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | ALTANA PHARMA AG (DE) | 2005-03-17 | — | — | WO | disclosed |
| CN-1152864-C | Phenylphenanthridines with PDE-IV inhibiting activity | ��̹��ҽҩ��˾ | 2004-06-09 | — | — | CN | disclosed |
| US-6476025-B1 | Phenylphennanthridines with PDE-IV inhibiting activity | ALTANA PHARMA AG (DE) | 2002-11-05 | — | — | US | disclosed |
| CN-1336919-A | Phenylphenanthridines with PDE-IV inhibiting activity | BYK GULDEN LOMBERG CHEM FAB (DE) | 2002-02-20 | — | — | CN | disclosed |
| EP-1147089-A1 | PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000042020-A1 | PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281745-A1 | Use of pde4 inhibitors for the treatment of diabetes mellitus | PDE4A, PDE4B, PDE12 | CA12 3531/4885CA2 2608/4885ENPP1 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.